Insilico Medicine Surges in Hong Kong Debut, Marking 2025’s Largest Biotech IPO

Hong Kong, Wednesday, 31 December 2025.
On December 30, 2025, Insilico Medicine (3696.HK) successfully listed on the Hong Kong Stock Exchange, raising HKD 2.277 billion ($293 million) in the year’s largest biotech IPO. The debut underscores robust investor appetite for AI-driven healthcare, with shares jumping significantly from the issue price of HKD 24.05 following a staggering 1,427-times oversubscription of the public offering. As the first AI-biotech firm listed under the HKEX’s Chapter 8.05 rules, this event marks a pivotal validation of generative AI in drug discovery. Proceeds are earmarked to accelerate clinical pipelines and enhance proprietary AI models. The listing coincides with a broader recovery in the region’s capital markets, highlighted by a 67% surge in the Hang Seng Biotech Index throughout 2025.